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Abstract
Introduction: Peroxisome proliferator-activated receptor (PPAR)g has been shown to exhibit anti-inflammatory and
anti-catabolic properties and to be protective in animal models of osteoarthritis (OA). We have previously shown
that interleukin-1b (IL-1) down-regulates PPARg expression in human OA chondrocytes. However, the mechanisms
underlying this effect have not been well characterized. The PPARg promoter harbors an overlapping Egr-1/
specificity protein 1 (Sp1) binding site. In this study, our objective was to define the roles of Egr-1 and Sp1 in IL-1-
mediated down-regulation of PPARg expression.
Methods: Chondrocytes were stimulated with IL-1 and the expression levels of Egr-1 and Sp1 mRNAs and proteins
were evaluated using real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting,
respectively. The role of de novo protein synthesis was evaluated using the protein synthesis inhibitor
cycloheximide (CHX). The recruitment of Sp1 and Egr-1 to the PPARg promoter was evaluated using chromatin
immunoprecipitation (ChIP) assays. The PPARg promoter activity was analyzed in transient transfection experiments.
The roles of Egr-1 and Sp1 were further evaluated using small interfering RNA (siRNA) approaches. The level of Egr-
1 in cartilage was determined using immunohistochemistry.
Results: Down-regulation of PPARg expression by IL-1 requires de novo protein synthesis and was concomitant
with the induction of the transcription factor Egr-1. Treatment with IL-1 induced Egr-1 recruitment and reduced
Sp1 occupancy at the PPARg promoter. Overexpression of Egr-1 potentiated, whereas overexpression of Sp1
alleviated, the suppressive effect of IL-1 on the PPARg promoter, suggesting that Egr-1 may mediate the
suppressive effect of IL-1. Consistently, Egr-1 silencing prevented IL-1-mediated down-regulation of PPARg
expression. We also showed that the level of Egr-1 expression was elevated in OA cartilage compared to normal
cartilage.
Conclusions: Our results indicate that induction and recruitment of Egr-1 contributed to the suppressive effect of
IL-1 on PPARg expression. They also suggest that modulation of Egr-1 levels in the joint may have therapeutic
potential in OA.
* Correspondence: h.fahmi@umontreal.ca
1Osteoarthritis Research Unit, Research Centre of the University of Montreal
Hospital Center (CR-CHUM), Notre-Dame Hospital, 1560 Sherbrooke Street
East, J.A. DeSève Pavillion, Y-2628, and Department of Medicine, University of
Montreal, Montreal, QC H2L 4M1, Canada
Full list of author information is available at the end of the article
Nebbaki et al. Arthritis Research & Therapy 2012, 14:R69
http://arthritis-research.com/content/14/2/R69
© 2012 Nebbaki et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Osteoarthritis (OA) is the most common joint disease
and is a leading cause of disability in developed countries
and throughout the world. Clinical manifestations of OA
may include pain, stiffness, and reduced joint motion.
Pathologically, OA is characterized by progressive degen-
eration of articular cartilage, synovial inflammation, and
subchondral bone remodeling. It is also characterized by
increased levels of inflammatory mediators, among which
interleukin 1 (IL-1) is considered a key player in the
initiation and progression of the disease [1].
The mechanisms through which IL-1 exerts its effects
include increased expression of inflammatory genes such
as inducible nitric oxide synthase (iNOS), cyclooxygenase
2 (COX-2), microsomal prostaglandin E synthase 1
(mPGES-1), and the release of nitric oxide (NO) and
prostaglandin E2 (PGE2) [1]. IL-1 also promotes cartilage
degradation by suppressing the synthesis of the major
components of extracellular matrix proteoglycan and col-
lagen and by enhancing the production of matrix metal-
loproteinases (MMPs) and aggrecanases [1].
Peroxisome proliferator-activated receptors (PPARs) are
a family of transcription factors belonging to the nuclear
hormone receptor superfamily, which includes receptors
for steroids, thyroid hormone, vitamin D, and retinoic
acid. Three PPAR isoforms have been identified: PPARa,
PPARb/δ, and PPARg [2]. PPARa, present primarily in the
liver, heart, and muscle, plays a central role in the regula-
tion of fatty acid metabolism [3]. PPARb/δ is ubiquitously
expressed and has been suggested to participate in various
physiological processes such as lipid homeostasis, epider-
mal maturation, tumorogenesis, wound healing, and brain
development [4]. PPARg, the most thoroughly studied
member of the PPAR family, exists as two forms as a
result of differential splicing: PPARg1 and PPARg2.
PPARg1 is expressed in several tissues and cell types,
whereas PPARg2 is found mainly in adipose tissues.
PPARg plays important modulatory roles in lipid and glu-
cose metabolism, cellular differentiation, vascular function,
and immunoregulation and has been implicated in various
conditions, including inflammation, atherosclerosis, and
cancer [5-7].
There is increasing evidence that PPARg also plays an
important role in the pathophysiology of OA and other
arthritic articular diseases [8]. Activation of PPARg inhibits
IL-1-induced NO and PGE2 production as well as iNOS
and COX-2 expression in human and rat chondrocytes
[9-12]. PPARg activation was also shown to suppress the
induction of mPGES-1, which catalyzes the terminal step
in PGE2 synthesis [13,14]. In addition to having effects on
inflammatory responses, PPARg activation modulates sev-
eral events involved in cartilage destruction. For instance,
PPARg activation was demonstrated to inhibit IL-1-
induced MMP-1, MMP-3, MMP-9, and MMP-13
expression [9,15,16] as well as IL-1-mediated proteoglycan
degradation [11]. Moreover, PPARg activation was
reported to prevent IL-1-mediated degradation of type II
collagen in human OA cartilage explants [16]. Additional
in vitro studies demonstrated that PPARg activation sup-
pressed several inflammatory and catabolic responses in
synovial fibroblasts, including the production of tumor
necrosis factor-alpha (TNF-a), IL-1, IL-6, IL-8, MMP-1,
and MMP-3 [17-19] and the expression of iNOS, cytosolic
phospholipase A2 (cPLA2), COX-2, and mPGES-1
[20-22]. Finally, the protective effects of PPARg in OA
have been proven in vivo in animal models of the disease.
In this context, we have demonstrated that PPARg activa-
tors reduced the size, depth, and histological severity of
cartilage lesions in two models of OA: the partial medial
meniscectomy in guinea pigs [23] and anterior cruciate
ligament transection in dogs [24].
We previously showed that IL-1 suppresses PPARg
expression in human OA chondrocytes [25]; however, the
underlying signaling mechanisms remained undefined.
The PPARg proximal promoter contains an overlapping
binding site for the transcription factors Egr-1 (early
growth response gene 1) and Sp1 (specificity protein 1). In
the present study, we demonstrated that Egr-1 contributes
to the suppressive effect of IL-1 on PPARg expression,
likely through displacement of prebound Sp1.
Materials and methods
Reagents and antibodies
Human recombinant IL-1 was obtained from Genzyme
(Cambridge, MA, USA). Aprotinin, leupeptin, pepstatin,
phenylmethylsulphonyl fluoride (PMSF), cycloheximide
(CHX), and sodium orthovanadate (Na3VO4) were from
Sigma-Aldrich Canada (Oakville, ON, Canada). Dulbecco’s
modified Eagle’s medium (DMEM), penicillin and strepto-
mycin, fetal calf serum (FCS), and Trizol reagents were
supplied by Invitrogen (Burlington, ON, Canada). Antibo-
dies against Egr-1, Sp1, and b-actin were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
The antibody against PPARg was from Cayman Chemical
Company (Ann Arbor, MI, USA). Polyclonal goat anti-rab-
bit immunoglobulin G (IgG) with horseradish peroxidase
(HRP) was from Pierce (Rockford, IL, USA).
Specimen selection and chondrocyte culture
Human normal cartilage (from femoral condyles) was
obtained at necropsy, within 12 hours of death, from
donors with no history of arthritic diseases (n = 12, mean
± standard deviation (SD) age: 61 ± 14 years). To ensure
that only normal tissue was used, cartilage specimens
were thoroughly examined both macroscopically and
microscopically. Only those with neither alteration were
further processed. Human OA cartilage was obtained
from patients undergoing total knee replacement (n = 31,
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mean ± SD age: 66 ± 15 years). In all patients, OA was
diagnosed on the basis of criteria developed by the Amer-
ican College of Rheumatology Diagnostic Subcommittee
for OA [26]. At the time of surgery, the patients had
symptomatic disease requiring medical treatment in the
form of non-steroidal anti-inflammatory drugs or selec-
tive COX-2 inhibitors. Patients who had received intra-
articular injections of steroids were excluded. The Clini-
cal Research Ethics Committee of Notre-Dame Hospital
approved the study protocol and the use of human
articular tissues. Informed consent was obtained from
each donor or from an authorized third party.
Chondrocytes were released from cartilage by sequen-
tial enzymatic digestion as previously described [25].
Cells were seeded at 3.5 × 105 cells per well in 12-well
culture plates (Costar, Corning, NY, USA) or at 6 to 7 ×
105 cells per well in six-well culture plates in DMEM
supplemented with 10% FCS and were cultivated at 37°C
for 48 hours. Cells were washed and incubated for an
additional 24 hours in DMEM containing 0.5% FCS
before stimulation with IL-1.
Western blot analysis
Chondrocytes were lysed in ice-cold lysis buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM ethylenediamine-
tetraacetic acid (EDTA), 1 mM PMSF, 10 μg/mL each of
aprotinin, leupeptin, and pepstatin, 1% NP-40, 1 mM
Na3VO4, and 1 mM NaF). Lysates were sonicated on ice
and centrifuged at 12,000 revolutions per minute for 15
minutes. The protein concentration of the supernatant
was determined by using the bicinchoninic acid method
(Pierce). Twenty micrograms of total cell lysate was sub-
jected to SDS-polyacrylamide gel electrophoresis and elec-
trotransferred to a nitrocellulose membrane (Bio-Rad,
Mississauga, ON, Canada). After blocking in 20 mM Tris-
HCl pH 7.5 containing 150 mM NaCl, 0.1% Tween 20,
and 5% (wt/vol) non-fat dry milk, blots were incubated
overnight at 4°C with the primary antibody and washed
with a Tris buffer (Tris-buffered saline (TBS) pH 7.5 with
0.1% Tween 20). The blots were then incubated with
HRP-conjugated secondary antibody (Pierce), washed
again, incubated with SuperSignal Ultra Chemilumines-
cent reagent (Pierce), and exposed to Kodak X-Omat film
(Eastman Kodak Company, Rochester, NY, USA).
RNA extraction and reverse transcriptase-polymerase
chain reaction
Total RNA from cultured chondrocytes or cartilage was
isolated by using the TRIzol reagent (Invitrogen) in accor-
dance with the instructions of the manufacturer. To
remove contaminating DNA, isolated RNA was treated
with RNase-free DNase I (Ambion, Austin, TX, USA). The
RNA was quantitated by using a RiboGreen RNA
quantitation kit (Molecular Probes Inc., now part of Invi-
trogen Corporation, Carlsbad, CA, USA), dissolved in
diethylpyrocarbonate-treated H2O, and stored at -80°C
until use. One microgram of total RNA was reverse-tran-
scribed by using Moloney murine leukemia virus reverse
transcriptase (Fermentas, Burlington, ON, Canada) as
detailed in the guidelines of the manufacturer. One fiftieth
of the reverse transcriptase reaction was analyzed by real-
time polymerase chain reaction (PCR) as described below.
The following primers were used: PPARg, sense, 5’-AAA-
GAAGCCAACACTAAACC-3’ and antisense, 5’-CTTC
CATTACGGAGAGATCC-3’; Egr-1, sense, 5’-CTGAC
CGCAGAGTCTTTTCCTG-3’ and antisense, 5’-TGGGT
GCCGCTGAGTAAATG-3’; Sp1, sense 5’-AAACATAT-
CAAAGACCCACCAGAAT-3’ and antisense 5’-ATATT
GGTGGTAATAAGGGCTGAA-3’; and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), sense 5’-CAGAAC
ATCATCCCTGCCTCT-3’ and antisense 5’-GCTTGA-
CAAAGTGGTCGTTGAG -3’.
Real-time polymerase chain reaction
Real-time PCR analysis was performed in a total volume of
50 μL containing template DNA, 200 nM of sense and
antisense primers, 25 μL of SYBR® Green master mix
(Qiagen, Mississauga, ON, Canada) and uracil-N-glycosy-
lase (UNG) (0.5 Units; Epicentre Technologies, Madison,
WI, USA). After incubation at 50°C for 2 minutes (UNG
reaction) and at 95°C for 10 minutes (UNG inactivation
and activation of the AmpliTaq Gold enzyme), the mix-
tures were subjected to 40 amplification cycles (15 seconds
at 95°C for denaturation and 1 minute for annealing and
extension at 60°C). Incorporation of SYBR® Green dye
into PCR products was monitored in real time by using a
GeneAmp 5700 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) and allowing determina-
tion of the threshold cycle (CT) at which exponential
amplification of PCR products begins. After PCR, dissocia-
tion curves were generated with one peak, indicating the
specificity of the amplification. A CT value was obtained
from each amplification curve by using the software pro-
vided by the manufacturer (Applied Biosystems).
Relative mRNA expression in chondrocytes was deter-
mined by using the ΔΔCT method, as detailed in the
guidelines of the manufacturer (Applied Biosystems). A
ΔCT value was first calculated by subtracting the CT value
for the housekeeping gene GAPDH from the CT value for
the gene of interest. A ΔΔCT value was then calculated by
subtracting the ΔCT value of the control (unstimulated
cells) from the ΔCT value of each treatment. Fold changes
compared with the control were then determined by rais-
ing 2 to the -ΔΔCT power. Each PCR generated only
the expected specific amplicon as shown by the melting-
temperature profiles of the final product and by gel
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electrophoresis of test PCRs. Each PCR was performed in
triplicate on two separate occasions for each independent
experiment.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) experiments
were performed according to the ChIP protocol provided
by Upstate/Millipore Biotechnology Inc. (Lake Placid,
NY, USA) and previously published protocols [27]. After
treatment, the cells were cross-linked with 1% formalde-
hyde for 10 minutes at room temperature. The fixed cells
were washed twice with ice-cold phosphate-buffered sal-
ine containing protease inhibitors and then lysed for
10 minutes at 1 × 106 cells per 200 μL of SDS lysis buffer
(50 mM Tris-Cl (pH 8.0), 0.5% SDS, 100 mM NaCl, and
5 mM EDTA) plus protease inhibitors. The chromatin
samples were sonicated to reduce DNA length to 200 to
500 base pairs (bp). Twenty microliters of the superna-
tant was saved as the input DNA, and the remainder was
diluted 1:10 in ChIP dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, and 16.7 mM Tris-Cl)
containing protease inhibitors. The chromatin samples
were precleared with a salmon sperm DNA/protein A-
agarose 50% gel slurry for 3 hours. The samples were
then immunoprecipitated overnight at 4°C with antibo-
dies specific for either Sp1 and Egr-1. As negative con-
trols, cross-linked chromatin was incubated overnight
with control Ig or in the absence of antibody. Immune
complexes were recovered by addition of salmon sperm
DNA/protein A-agarose slurry for 2 hours at 4°C. The
immune complexes were sequentially washed three times
each (5 minutes on a rotating platform), with low salt,
high salt, lithium chloride, and Tris/EDTA buffers, and
eluted twice with 250 μL of 1% SDS and 0.1 M NaHCO3
for 15 minutes. The eluted material and the DNA input
samples were heated for 4 hours at 65°C to reverse cross-
linking. The samples were treated with 40 μg/mL DNase-
free proteinase K for 1 hour at 45°C, extracted with phe-
nol-chloroform-isoamyl alcohol and chloroform, and
ethanol-precipitated in the presence of 20 μg of glycogen.
Pellets were suspended in 25 to 30 μL of H2O and sub-




The luciferase reporter construct pGL3-PPARg1p3000,
containing a 3,000-bp fragment of the human PPARg1
gene promoter, was kindly provided by Johan Auwerx
(Institut de Génétique et de Biologie moléculaire et Cellu-
laire, Illkirch, France). Egr-1 expression vector (pcDNA3)
was donated by Yuqing Chen (Morehouse School of Medi-
cine, Atlanta, GA, USA) [28]. The b-galactosidase reporter
vector under the control of SV40 promoter (pSV40-b-gal)
was from Promega Corporation (Madison, WI, USA).
Transient transfection experiments were performed by
using the FuGene-6 transfection reagent in accordance
with the recommended protocol of the manufacturer
(Roche Applied Science, Indianapolis, IN, USA). Briefly,
chondrocytes were seeded 24 hours prior to transfection
at a density of 3 × 105 cells per well in 12-well plates and
transiently transfected with 1 μg of the PPARg promoter
construct and 0.5 μg of the internal control pSV40-b-gal.
Six hours later, the medium was replaced with DMEM
containing 1% FCS. At 1 day after transfection, the cells
were left untreated or treated with IL-1 (100 pg/mL) for
20 hours. In the overexpression experiments, the amount
of transfected DNA was kept constant by using the corre-
sponding empty vector. At the end of the indicated treat-
ment, the cells were washed twice in ice-cold phosphate-
buffered saline (PBS) and extracts were prepared for firefly
luciferase reporter assay (Promega Corporation). Lucifer-
ase activity was normalized for transfection efficiency by
using the corresponding b-galactosidase activity.
RNA interference
Specific small interfering RNA (siRNA) for Sp1, Egr-1, or
scrambled control was obtained from Dharmacon Inc.
(Lafayette, CO, USA). Chondrocytes were seeded in six-
well plates at 6 × 105 cells per well and incubated for
24 hours. Cells were transfected with 100 nM of siRNA by
using the HiPerFect Transfection Reagent (Qiagen) in
accordance with the recommendations of the manufac-
turer. The medium was changed 24 hours later, and the
cells were incubated for an additional 24 hours before sti-
mulation with 100 pg/mL IL-1 for 1 or 20 hours.
Immunohistochemistry
Cartilage specimens were processed for immunohisto-
chemistry as previously described [25]. The specimens
were fixed in 4% paraformaldehyde and embedded in par-
affin. Sections (5 μm) of paraffin-embedded specimens
were deparaffinized in toluene and dehydrated in a graded
series of ethanol. The specimens were then preincubated
with chondroitinase ABC (0.25 U/mL in PBS pH 8.0) for
60 minutes at 37°C followed by a 30-minute incubation
with Triton X-100 (0.3%) at room temperature. Slides
were then washed in PBS followed by incubation with 2%
hydrogen peroxide/methanol for 15 minutes. They were
further incubated for 60 minutes with 2% normal serum
(Vector Laboratories, Burlingame, CA, USA) and overlaid
with an anti-Egr-1 antibody (Santa Cruz Biotechnology,
Inc.) for 18 hours at 4°C in a humidified chamber. Each
slide was washed three times in PBS pH 7.4 and stained by
using the avidin-biotin complex method (Vectastain ABC
kit; Vector Laboratories). The color was developed with
3,3’-diaminobenzidine (Vector Laboratories) containing
hydrogen peroxide. The slides were counterstained with
Nebbaki et al. Arthritis Research & Therapy 2012, 14:R69
http://arthritis-research.com/content/14/2/R69
Page 4 of 13
eosin. The specificity of staining was evaluated by using an
antibody that had been preadsorbed (1 hour at 37°C) with
a 20-fold molar excess of the protein fragment corre-
sponding to amino acids 500 to 550 of human Set1A
(Santa Cruz Biotechnology, Inc.) and by substituting the
primary antibody with non-immune rabbit IgG (Chemi-
con, Temecula, CA, USA), used at the same concentration
as the primary antibody. The evaluation of positive-stain-
ing chondrocytes was performed by using our previously
published method [25]. For each specimen, six micro-
scopic fields were examined under 40× magnification. The
total number of chondrocytes and the number of chon-
drocytes staining positive were evaluated, and results were
expressed as the percentage of chondrocytes staining posi-
tive (cell score).
Statistical analysis
Data are expressed as the mean ± SD. Statistical signifi-
cance was assessed by the two-tailed Student t test.
P values of less than 0.05 were considered significant.
Results
Downregulation of PPARg expression by IL-1 requires de
novo protein synthesis
First, we investigated whether IL-1-mediated downregu-
lation of PPARg expression in chondrocytes requires de
novo protein synthesis. Chondrocytes were incubated
with cycloheximide (10 μg/mL) for 30 minutes prior to
stimulation with 100 pg/mL IL-1 for 18 hours, and the
levels of PPARg mRNA were analyzed by real-time PCR.
Changes in PPARg mRNA gene expression were evalu-
ated as percentage over control (untreated cells) after
normalization to the internal control gene, GAPDH. As
shown in Figure 1, stimulation with IL-1 down-regulated
PPARg mRNA expression to approximately 80% of con-
trol (bar 2 versus bar 1), confirming our earlier findings
[25]. Treatment with CHX prevented IL-1-mediated
suppression of PPARg mRNA expression (bar 4 versus
bar 2), suggesting that the suppressive effect of IL-1 on
PPARg was an indirect effect and was dependent on de
novo protein synthesis.
Downregulation of PPARg expression by IL-1 correlated
with increased Egr-1 expression
Analysis of the PPARg promoter identified a putative Egr-
1-binding site, which overlaps with a Sp1-binding site,
between nucleotide-184 and -173 relative to the transcrip-
tion start site. To evaluate the role of these transcription
factors in the suppressive effect of IL-1 on PPARg expres-
sion, we first examined the effect of IL-1 on their expres-
sion in chondrocytes. Cells were treated with IL-1 for
different time periods, and the levels of Egr-1 mRNA were
quantified by using real-time reverse transcriptase-PCR
(RT-PCR). IL-1-induced changes in gene expression were
evaluated as fold over control (untreated cells) after nor-
malization to the internal control gene, GAPDH. As shown
in Figure 2a, treatment with IL-1 enhanced Egr-1 mRNA
expression in a time-dependent manner. Egr-1 mRNA was
rapidly and significantly induced at 0.5 hours post-stimula-
tion with IL-1, reached the maximum at 1 hour, and
started to decrease at 2 hours. Next, we performed Wes-
tern blot analysis to determine whether changes in mRNA
levels were paralleled by changes in Egr-1 protein levels.
Consistent with its effects on Egr-1 mRNA, IL-1 induced
Egr-1 protein expression in a time-dependent manner (Fig-
ure 2d). Egr-1 protein levels were significantly increased by
0.5 hours post-stimulation, further increased up to 1 hour,
then gradually declined starting at 2 hours, and reached
basal levels at 8 hours. The induction of Egr-1 mRNA by
IL-1 was also dose-dependent (data not shown). These
results indicated that IL-1 is a potent inducer of Egr-1
mRNA and protein expression in human chondrocytes. In
contrast, IL-1 had no significant effect on the expression
levels of Sp1 mRNA and protein (Figure 2b,e). Importantly,
the induction of Egr-1 protein expression by IL-1 preceded
the suppression of PPARg expression (Figure 2c,f). The
correlation between the downregulation of PPARg expres-
sion and the induction of Egr-1 suggests a link between
these two events.
IL-1 induced the recruitment of Egr-1 and decreased Sp1
occupancy at the PPARg promoter
To determine whether Egr-1 and Sp1 proteins physically
interact with the PPARg promoter in vivo, we performed
IL-1                    -                    +                     -                    + 























Figure 1 IL-1-mediated downregulation of PPARg mRNA
expression requires de novo protein synthesis. Chondrocytes
were incubated with cycloheximide (10 μg/mL) for 30 minutes prior
to stimulation with 100 pg/mL IL-1 for 18 hours. Total RNA was
isolated and was reverse-transcribed into cDNA, and PPARg mRNA
was quantified by using real-time polymerase chain reaction. Results
are expressed as percentage of control (100 is considered the value
of untreated cells) and represent the mean ± standard deviation of
four independent experiments. *P < 0.05 compared with cells
treated with IL-1 alone. CHX, cycloheximide; IL, interleukin; PPARg,
peroxisome proliferator-activated receptor gamma.
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ChIP assays. Chondrocytes were stimulated with IL-1 for
various time periods, and formaldehyde-cross-linked
DNA-proteins were immunoprecipitated by using antibo-
dies specific to Egr-1 and Sp1. Control Ig and no antibody
were used as controls. DNA isolated from the immuno-
precipitates was analyzed by real-time PCR by using pri-
mers amplifying the PPARg promoter region (bp -322 to
-139) that harbors the overlapping Sp1/Egr-1 site.
As shown in Figure 3b, treatment with IL-1 enhanced
the levels of Egr-1 at the PPARg promoter in a time-
dependent manner. It started to increase significantly at
1 hour after IL-1 stimulation, reached a maximum at
2 hours, and returned to a near basal level by 8 hours. In
contrast, the levels of Sp1 at the PPARg promoter
decreased after IL-1 stimulation (Figure 3c). Sp1 levels
were significantly decreased by 2 hours after stimulation,
with a further decrease at 4 hours, and remained downre-
gulated until the 18-hour time point. No immunoprecipi-
table PPARg promoter DNA was detected with the control
Ig and no antibody controls (data not shown).
The recruitment of Egr-1 and reduced occupancy of Sp1
at the PPARg promoter preceded the suppression of PPARg
transcription by IL-1, suggesting that the recruitment of
Egr-1 mediates PPARg downregulation. Taken together,
these results strongly suggest that IL-1-mediated downre-
gulation of PPARg involves the recruitment of Egr-1 and
reduced occupancy of Sp1.
Overexpression of Egr-1 suppressed, whereas that of Sp1
enhanced, PPARg promoter activity
To further characterize the functional roles of Sp1 and
Egr-1 in IL-1-mediated downregulation of PPARg
expression, we performed transient transfection experi-
ments in which we examined the effects of Egr-1 and
Sp1 on PPARg promoter activity. Chondrocytes were
transiently co-transfected with the PPARg promoter and
increasing concentrations of expression vectors that
encode Sp1 or Egr-1, and at 18 hours post-transfection,
the cells were left untreated or stimulated with IL-1 for
an additional 18 hours.
As shown in Figure 4a, treatment with IL-1 suppressed
PPARg promoter activity (bar 5 versus bar 1), consistent
with previous data [25]. Overexpression of Egr-1 had no
significant effect on the basal PPARg promoter activity
(bars 2 to 4) but dose-dependently potentiated the sup-
pressive effect of IL-1 (bars 6 to 8). These data suggest
that Egr-1 mediates the suppressive effect of IL-1 on
PPARg expression. In contrast, overexpression of Sp1
slightly enhanced (bars 2 to 4) the basal activity of the
PPARg promoter and prevented (bars 6 to 8) the suppres-
sive effect of IL-1 on the PPARg promoter activity (Figure
4b). These data corroborate the ChIP data, suggesting
that Egr-1 mediates the suppressive effect of IL-1 on
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Figure 2 Effect of IL-1 on Egr-1 and Sp1 expression in osteoarthritis chondrocytes. Chondrocytes were treated with 100 pg/mL IL-1 for
the indicated time periods. Total RNA was isolated and was reverse-transcribed into cDNA, and Egr-1 (a), Sp1 (b), and PPARg (c) mRNAs were
quantified by using real-time polymerase chain reaction. All experiments were performed in triplicate, and negative controls without template
RNA were included in each experiment. (a,b) Results are expressed as fold change, and 1 is considered the value of control (that is, untreated
cells). (c) Results are expressed as percentage of control (that is, cells treated with IL-1 alone) and are the mean ± SD from four independent
experiments. The results represent the mean ± SD of four independent experiments. *P < 0.05 compared with unstimulated cells. Cell lysates
were prepared and analyzed for Egr-1 (d), Sp1 (e), and PPARg (f) protein expression by Western blotting. In the lower panels, the blots were
stripped and reprobed with a specific anti-b-actin antibody. The blots are representative of similar results obtained from four independent
experiments. Egr-1, early growth response gene 1; IL, interleukin; PPARg, peroxisome proliferator-activated receptor gamma; SD, standard
deviation; Sp1, specificity protein 1.
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Figure 3 Effect of IL-1 on the recruitment of Egr-1 and Sp1 at the PPARg promoter. (a) Schematic diagram of the PPARg promoter
showing the locations of the overlapping binding site for Egr-1 and Sp1. Arrows indicate primers used for ChIP analysis. (b,c) Confluent
chondrocytes were treated with 100 pg/mL IL-1 for the indicated time periods, and ChIP assays were performed by using specific anti-Egr-11 (a)
and anti-Sp1 (b) antibodies. (a) The results are expressed as fold change of Egr-1 binding to the PPARg promoter relative to untreated cells and
represent the mean ± SD of four independent experiments. (b) Results are expressed as percentage of control (that is, untreated cells) and are
the mean ± SD of four independent experiments. *P < 0.05 compared with unstimulated cells. ChIP, chromatin immunoprecipitation; Egr-1, early
growth response gene 1; IL, interleukin; PPARg, peroxisome proliferator-activated receptor gamma; SD, standard deviation; Sp1, specificity
protein 1.
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Egr-1 silencing with siRNA mitigated IL-1-mediated
suppression of PPARg expression
To further confirm the role of Egr-1, we examined the
impact of its silencing by siRNA on IL-1-mediated
downregulation of PPARg protein expression. Chondro-
cytes were transfected with the scrambled control
siRNA, siRNA for Sp1, or siRNA for Egr-1, and after 48
hours of transfection, the cells were stimulated or not
with IL-1 for 1 or 18 hours. As shown in Figure 5,
transfection with Egr-1 siRNA reversed the suppressive
effect of IL-1 on PPARg. In contrast, transfection with
Sp1 siRNA or with scrambled control siRNA had no
effect. Sp1 protein levels were reduced by as much as
70% to 75%, and Egr-1 protein levels were almost com-
pletely suppressed, confirming silencing of both genes
(Figure 5). Together, these data clearly show that Egr-1
is required for IL-1-mediated downregulation of PPARg
protein expression.
Egr-1 levels are elevated in osteoarthritis cartilage
To determine whether Egr-1 levels were altered under
OA conditions, we analyzed the levels of Egr-1 mRNA
in total cartilage from normal (n = 9) and OA (n = 9)
donors by using real-time quantitative RT-PCR. As
shown in Figure 6a, the level of Egr-1 mRNA was
approximately 3.5-fold higher in OA cartilage compared
with normal cartilage. Next, we used immunohisto-
chemistry to analyze the localization and the expression
level of Egr-1 protein in normal and OA cartilage. As
shown in Figure 6c and 6d, Egr-1 was expressed primar-
ily in chondrocytes of the superficial and upper inter-
mediate zones of the cartilage. Statistical evaluation for
the cell score revealed that the percentage of cells
expressing Egr-1 was approximately 3-fold higher in OA
cartilage (n = 9) compared with normal cartilage (n =
9). The specificity of the staining was confirmed by
using an antibody that had been preadsorbed (1 hour at
37°C) with a 20-fold molar excess of the peptide antigen
or non-immune control IgG (data not shown). Together,
these data indicate that the expression level of Egr-1 is
increased in OA cartilage.
Discussion
The transcription factor PPARg has been shown to mod-
ulate a number of inflammatory and catabolic responses
in articular joint tissues and was suggested to be protec-
tive in OA and other arthritic diseases [14-32]. Although
many stimuli have been reported to regulate the expres-
sion of PPARg in several cell types (including chondro-
cytes) [8], little is known about the details of the exact
mechanisms that govern its expression.
In the present study, we investigated the roles of the
transcription factors Egr-1 and Sp1 in the downregula-
tion of PPARg expression by IL-1. We demonstrated
that IL-1-mediated downregulation of PPARg coincided












































Figure 4 Effect of Sp1 and Egr-1 on PPARg promoter activity. Chondrocytes were co-transfected with the human PPARg promoter (1 μg/
well) and the internal control pSV40-b-gal (0.5 μg/well) together with increasing concentrations of an expression vector for Egr-1 (a) or Sp1 (b).
The total amount of transfected DNA was kept constant by addition of the empty vector. The next day, transfected cells were treated with IL-1
(100 pg/mL) for 18 hours. Luciferase activity values were determined and normalized to b-galactosidase activity. Results are expressed as
percentage of control (100 is considered the value of untreated cells) and represent the mean ± SD of four independent experiments. *P < 0.05
compared with cells treated with IL-1 alone (control). Egr-1, early growth response gene 1; IL, interleukin; PPARg, peroxisome proliferator-
activated receptor gamma; SD, standard deviation; Sp1, specificity protein 1.
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downregulation of PPARg expression was preceded by
Egr-1 recruitment to, and concomitant reduced Sp1
occupancy at, the PPARg promoter. Overexpression of
Egr-1 suppressed, whereas that of Sp1 enhanced, PPARg
promoter activity. Furthermore, Egr-1 silencing pre-
vented the downregulation of PPARg expression by IL-1.
Together, these data indicate that Egr-1 mediates the
suppressive effect of IL-1 on PPARg expression, likely
through displacement of Sp1.
The PPARg promoter contains an overlapping Sp1/Egr-
1-binding site. The transcription factor Sp1 is ubiqui-
tously expressed in cell lines and tissues and generally
functions as an activator of transcription [29]. The tran-
scription factor Egr-1 is not expressed in normal tissues
but is rapidly induced by inflammatory cytokines and
growth factors [30-33]. In promoters containing overlap-
ping Sp1/Egr-1-binding sites, Egr-1 can function as a
transcriptional activator or repressor. For example, Egr-1
has been shown to compete with Sp1 for an overlapping
region in the promoter of platelet-derived growth factor-
A (PDGF-A) and activates transcription in vascular
endothelial cells [34]. Egr-1-mediated transcriptional
activation through displacement of Sp1 was also observed
for N-myc downregulated gene (NDRG1) [35] and tissue
factor [36]. In contrast, other studies reported that Egr-1
competes with Sp1 and represses the transcription of a
number of genes, including the b-adrenergic receptor
[37], protein tyrosine phosphatase 1B [38], sterol regula-
tory element-binding protein 1 (SREBP-1) [39], the ade-
nosine 5’-triphosphate-binding cassette transporter 2
(ABCA2) [40], and type II collagen [31].
Here, we found that treatment of chondrocytes with IL-
1 led to a time-dependent increase in Egr-1 expression,
whereas the expression of Sp1 was not altered. This is
consistent with previous studies showing that IL-1 is a
potent inducer of Egr-1 expression in the chondrocyte cell
line C-28/I2 [31]. We then examined the effect of IL-1 on
the recruitment of Egr-1 and Sp1 to the PPARg promoter.
ChIP results demonstrated that IL-1 induced Egr-1
recruitment to the PPARg promoter with a parallel reduc-
tion in Sp1 occupancy, indicating that Egr-1 displaced the
binding of Sp1. It is noteworthy that these changes at the
PPARg promoter were concomitant with the decrease in
PPARg expression, suggesting that Egr-1 recruitment to
the PPARg promoter could mediate the suppressive effect
of IL-1 on PPARg expression.
Using reporter gene assays, we found that IL-1 down-
regulated PPARg promoter activity and this effect was
further potentiated by co-transfection with an expression
vector for Egr-1. In contrast, Sp1 overexpression mitigated
the suppressive effect of IL-1. This confirms the respective
negative and positive regulation of the PPARg promoter
by Egr-1 and Sp1.
It should be noted that, in the absence of IL-1, transfec-
tion with Egr-1 had no effect on PPARg promoter activ-
ity, indicating that Egr-1 needs to be activated to achieve
inhibition of PPARg promoter activity. In this context, it
has been reported that the effects of Egr-1 on transcrip-
tion are modulated through its phosphorylation by casein
kinase II [41] and extracellular signal-regulated kinase
(Erk) [42]. Egr-1 activity can also be regulated through
acetylation, methylation, and ubiquitination, which are
known for their impact on the activity of a number of
proteins, including transcription factors. Indeed, Egr-1
harbors several consensus sites for acetylation and
methylation. Further studies are needed to determine
whether the repressive effect of Egr-1 on PPARg expres-
sion involves such post-translational modifications.
Collectively, these results strongly suggest that the
induction of Egr-1 expression and its recruitment to the
PPARg promoter mediate the suppressive effect of IL-1 on
PPARg expression. This is further supported by the fact
that siRNA-mediated silencing of Egr-1 blocked IL-1-
induced downregulation of PPARg protein expression.
There are a number of potential mechanisms through
which Egr-1 could mediate the downregulation of PPARg
expression by IL-1. The first possibility is that Egr-1 can
repress transcription by displacing prebound Sp1. This is
corroborated by our finding that the recruitment of Egr-1
to the PPARg promoter paralleled reduced Sp1 occu-







          IL-1               -      +       -       +      -        +      -      +   
Control siRNA         -       -      +       +       -       -       -      - 
  Egr-1 siRNA         -       -       -       -       -        -       +     + 
     Sp1 siRNA         -       -       -       -       +       +       -      - 
Figure 5 Egr-1 is required for IL-1-mediated suppression of
PPARg expression. Chondrocytes were transfected with 100 nM of
control scrambled siRNA, Sp1 siRNA, or Egr-1 siRNA. At 24 hours
after transfection, cells were washed, reincubated for another 24
hours, and left untreated or treated with 100 pg/mL IL-1 for 1 or 18
hours. Cell lysates were prepared and analyzed for Egr-1, Sp1 (1-
hour treatment), and PPARg (18-hour treatment) protein expression
by Western blotting. In the lower panels, the blots were stripped
and reprobed with a specific anti-b-actin antibody. The blots are
representative of similar results obtained from four independent
experiments. Egr-1, early growth response gene 1; IL, interleukin;
PPARg, peroxisome proliferator-activated receptor gamma; siRNA,
small interfering RNA; Sp1, specificity protein 1.
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through competition with promoter-associated Sp1, Egr-
1 represses transcription of genes that harbor overlapping
binding sites for Egr-1/Sp1 [34-36]. Secondly, Egr-1 may
inhibit PPARg expression through direct binding to Sp1
and inhibition of its transcriptional activity. In this con-
text, Egr-1 has been shown to inhibit Sp1 transcriptional
activity, independently of DNA binding, through
mechanisms that involve protein-protein interactions
[41]. Thirdly, Egr-1 can also repress transcription by
interfering with the interaction between Sp1 and TATA-
binding proteins (TBPs). Indeed, Sp1 has been shown to
interact with TBPs [43], and Egr-1 was reported to inhi-
bit the binding of TBPs to target promoters [44]. Finally,
Egr-1 can attenuate Sp1 activities by competing for
limited amounts of general transcriptional co-activators.
Of note, Egr-1 has been reported to repress transcription
by disrupting the interaction between Sp1 and CREB-
binding protein (CBP/p300) [31]. It is noteworthy that
the overlapping binding site for Sp1 and Egr-1 in the
PPARg promoter can also bind the transcription factor
Sp3. Indeed, Sp3 and Sp1 recognize and bind to the same
DNA element with similar affinity and their DNA-bind-
ing domains share over 90% DNA sequence homology.
Therefore, it is possible that Sp3 contributes to the regula-
tory effect of IL-1 on PPARg expression. Indeed, IL-1
induces Sp3 expression and Sp3 down-regulates the tran-
scriptional activity of Sp1 in chondrocytes. Such a mechan-
ism was documented in IL-1-induced downregulation of
A B 
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Figure 6 Expression of Egr-1 in normal and OA cartilage. (a) RNA was extracted from normal (n = 9) and OA (n = 9) cartilage, reverse-
transcribed into cDNA, and processed for real-time polymerase chain reaction. The threshold cycle values were converted to the number of
molecules. Data were expressed as copies of the gene’s mRNA detected per 10,000 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) copies.
*P < 0.05 versus normal samples. (b) Percentage of chondrocytes expressing Egr-1 in normal and OA cartilage. The results are the mean ±
standard deviation of nine normal and nine OA specimens. *P < 0.05 versus normal cartilage. Representative immunostaining of human normal
(c) and OA (d) cartilage for Egr-1 protein. Egr-1, early growth response gene 1; OA, osteoarthritis.
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type II transforming growth factor-beta (TGF-b) receptor
[45]. In addition to containing the overlapping Sp1/Egr-1-
binding sites, the PPARg promoter contains binding sites
for other transcription factors known to be activated by
IL-1, including activation protein-1 (AP-1), nuclear factor-
kappa-B (NF-B), nuclear factor of activated T cells (NF-
AT), and myogenic differentiation 1 (MyoD). Although the
role of these elements in IL-1-mediated downregulation of
PPARg expression is still unknown, we cannot exclude the
possibility that activation of these transcription factors by
IL-1 also participates in the downregulation of PPARg
expression. This is supported by the observation that
siRNA-mediated silencing of Egr-1 did not completely
reverse the suppressive effect of IL-1 on PPARg expression.
The involvement of Egr-1 in IL-1-mediated downregu-
lation of PPARg expression may be of relevance for
other stimuli known to modulate PPARg expression. For
instance, TNF-a and oxidative stress are known to
down-regulate PPARg expression [46,47]. Interestingly,
TNF-a and oxidative stress are potent inducers of Egr-1
expression [30,48]. Therefore, it is possible that the
induction of Egr-1 expression is part of the mechanisms
by which TNF-a and oxidative stress down-regulate
PPARg expression.
Several studies have suggested roles for Egr-1 in the
regulation of several genes involved in the pathogenesis
of arthritis. For example, Egr-1 was shown to mediate
TNF-a-induced MMP-9 [32], IL-1-mediated suppression
of type II collagen [31], and TNF-a-mediated suppres-
sion of aggrecan [33]. Egr-1 was also shown to positively
regulate several inflammatory responses. Indeed, Egr-1
mediates IL-1-induced mPGES-1 expression and PGE2
production in several cell types, including chondrocytes
and synovial fibroblasts [22]. Furthermore, Egr-1 contri-
butes to lipopolysaccharide-induced transcription of sup-
pressor of cytokine signaling-1 (SOCS-1), a key regulator
of lipopolysaccharide-induced cytokine production [49].
Egr-1 was also demonstrated to play a critical role in the
induction of a number of chemokines [50] and cytokines,
including IL-2, TNF-a [51], IL-6, granulocyte colony-sti-
mulating factor, and intracellular adhesion molecule [52].
In addition to inflammatory and catabolic responses,
chondrocyte apoptosis plays a significant role in the
pathogenesis of OA. Of importance, Egr-1 was shown to
positively regulate the expression of several pro-apoptotic
factors, including TNF-a-related apoptosis-inducing
ligand (TRAIL) [53] and phosphatase and tensin homo-
log (PTEN) [54]. These data, together with our findings
that Egr-1 mediates the suppressive effect of IL-1 on
PPARg expression, suggest that therapeutic interventions
that control Egr-1 expression may have protective effects
in OA. Further in vivo studies will be required to eluci-
date the exact role of Egr-1 in cartilage integrity and the
pathogenesis of OA.
Finally, we showed that OA cartilage expresses high
levels of Egr-1 compared with normal tissue. Positive
immunoreactive staining for Egr-1 was located primarily
in chondrocytes of the superficial layers. Interestingly,
the levels of IL-1, a key player in the pathogenesis of OA,
were reported to be elevated in these regions [55], sug-
gesting that IL-1 may be responsible for the observed
increase in Egr-1 in OA cartilage. This is consistent with
our findings that IL-1 is a potent inducer of Egr-1 expres-
sion in cultured chondrocytes. Our results are consistent
with the findings of Trabandt and colleagues [56], who
showed elevated Egr-1 expression in rheumatoid syno-
vium, which is characterized by increased production of
inflammatory cytokines. In contrast, Wang and collea-
gues [57] reported reduced expression of Egr-1 in OA
cartilage. These apparent discrepancies in the expression
of Egr-1 may be due to differences in study design.
Indeed, Wang and colleagues [57] performed their
immunohistochemical study by using cartilage from two
donors: one OA and one normal. The discrepancies may
also lie in differences in tissue processing, antibody con-
centrations, or staining detection methodology.
Conclusions
These data suggest that Egr-1 mediates the suppressive
effect of IL-1 on PPARg expression through a mechanism
involving displacement of prebound Sp1. They also sug-
gest that this pathway could be a potential target for phar-
macologic intervention in the treatment of OA and
possibly other arthritic diseases.
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